Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide...
CNN gets it spot on
CNN’s Meg Tirrell gets to the heart of the matter in “The end of a shortage of popular weight-loss drugs may mean many people lose access to them.” She focuses on patients who have come to rely on compounded tirzepatide and how they might be priced out of Lilly’s brand-name versions.
Bonus: The article quotes both CEO Scott Brunner and board member Jennifer Burch.
